USP Issues Explanatory Statement Regarding Recall of USP 33–NF 28 - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

USP Issues Explanatory Statement Regarding Recall of USP 33–NF 28


ePT--the Electronic Newsletter of Pharmaceutical Technology

The US Pharmacopeia released a statement this week that explains in more detail last January’s recall of the United States Pharmacopeia 33–National Formulary 28 (USP 33–NF 28). The statement also discusses steps to ensure the quality of future USPNF volumes.

The recall of the USP 33–NF 28 volume was made after errors were discovered in the publication (See back story, “USP Recalls Latest Monographs”. “These errors occurred as a result of an initiative known as the Monograph Redesign Project, in which all of the monographs in the compendia were redesigned to streamline presentation, improve the ease of use, and update and harmonize terminology,” according to the USP statement on the subject.

Since the recall, USP’s management, a Board-appointed task force (consisting of Board, USP Convention, and USP Council of Experts volunteers), and an independent law firm have performed three separate evaluations to examine factors that led to the errors, including the role of the Monograph Redesign Project. The three teams reached similar conclusions, some of which are highlighted below.

  • -“The Monograph Redesign Project proved to be far more complicated than originally thought…. At the outset, a decision not to include experienced scientific liaisons in the redesign project for USP–NF, as was done with the redesign of USP's Food Chemicals Codex (FCC) standards, precluded a full understanding of the magnitude of the task.”        
  • “The Project was not handled through USP's normal systems and management processes. As a result, typical quality assurance protections and controls were not utilized.”   
  • “USP senior management was not adequately involved in supervising the Project and there was a lack of clear accountability and responsibility. The Project lacked a strong, cross-functional management team to ensure organization-wide oversight.”

The evaluation teams proposed several corrective and preventative actions to ensure the future success of the Monograph Redesign Project, which will continue. Among the recommendations are: to include scientific liaisons who have intimate knowledge of the monographs in the redesign work (USP plans to add new staff to ensure adequate resources); to make division chiefs ultimately responsible and accountable for the redesign work; to implement a new automated workflow system that will track the monographs; to make the staff aware of the project’s importance; and to establish a quality assurance group that will perform regular process audits to the project before republication of the USPNF volumes. In addition, rather than redesigning all of the monographs at once, they will be redesigned based on priority over several years. The overall project completion target is 2015.

The full conclusions and recommendations can be reviewed on the USP website. In the USP statement, Board Chair Duane Kirking, PhD, said he is “convinced that the redesign project remains vital to improved usability of these important compendia—and that USP management and staff are ready, willing, and able to move this project forward with assurance of accuracy.”
 

ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
FDASIA was signed into law two years ago. Where has the most progress been made in implementation?
Reducing drug shortages
Breakthrough designations
Protecting the supply chain
Expedited reviews of drug submissions
More stakeholder involvement
Reducing drug shortages
35%
Breakthrough designations
12%
Protecting the supply chain
35%
Expedited reviews of drug submissions
12%
More stakeholder involvement
6%
View Results
Jim Miller Outsourcing Outlook Jim Miller Health Systems Raise the Bar on Reimbursing New Drugs
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerThe Mainstreaming of Continuous Flow API Synthesis
Jill Wechsler Regulatory Watch Jill Wechsler Industry Seeks Clearer Standards for Track and Trace
Siegfried Schmitt Ask the Expert Siegfried SchmittData Integrity
NIH Translational Research Partnership Yields Promising Therapy
Clusters set to benefit from improved funding climate but IP rights are even more critical
Supplier Audit Program Marks Progress
FDA, Drug Companies Struggle with Compassionate Use Requests
USP Faces New Challenges
Source: ePT--the Electronic Newsletter of Pharmaceutical Technology,
Click here